Circassia settles LungFit dispute with Beyond Air
26th May 2021 12:14
(Sharecast News) - Respiratory diagnostics-focussed medical device company Circassia Group has signed an agreement to settle its contractual dispute with Beyond Air, it announced on Wednesday, around the licensing of the 'LungFit' product to Circassia by Beyond Air in January 2019.
Read moreCircassia shares rise as it flags 'significant' revenue growth
9th Jan 2020 12:03
(Sharecast News) - Respiratory disease-focussed pharmaceutical company Circassia Pharmaceuticals updated the market on its trading for the year ended 31 December on Thursday, announcing that it expected revenues for the year to fall in the mid-range of its previously issued guidance of between £60m and £65m.
Read moreAdams increases stake in Circassia
3rd Jan 2020 14:41
(Sharecast News) - Adams announced on Friday that, on 2 January, it purchased an additional 2,400,000 ordinary shares in Circassia on the AIM market, at an average price of 19p per share, for a total cash consideration of £0.46m.
Read moreCircassia shares plunge as its partner terminates agreement
19th Dec 2019 16:44
(Sharecast News) - Specialty biopharmaceutical company Circassia Pharmaceuticals updated the market on its licensing agreement with BeyondAir, previously AIT Therapeutics, on Thursday.
Read moreCircassia posts jump in Q1 sales ahead of Duaklir launch in second half
1st May 2019 07:34
(Sharecast News) - Circassia narrowed its full-year loss as the company prepares for the launch of Duaklir later in the year, which some analysts believed held the key to putting the company on a firm and sustainable footing going forward, .
Read moreAmerica's FDA approves Circassia's latest respiratory treatment
1st Apr 2019 13:19
(Sharecast News) - Circassia Pharmaceuticals announced on Monday that the US Food and Drug administration had approved its latest treatment for obstructive pulmonary disease called Duaklir.
Read moreCircassia acquires rights to 'AirNOvent' in US and China
24th Jan 2019 09:27
(Sharecast News) - Specialty pharmaceutical company Circassia Pharmaceuticals has entered into a definitive agreement to acquire exclusive commercialisation rights from AIT Therapeutics to its ventilator compatible nitric oxide product, 'AirNOvent', in the United States and China, it announced on Thursday.
Read moreCircassia Pharmaceuticals outlines plans for a busy 2019
4th Jan 2019 14:38
(Sharecast News) - Specialty pharmaceutical company Circassia Pharmaceuticals updated the market on its current trading on Friday, reporting that it ended the year with cash, cash equivalents and short-term deposits of approximately £41m.
Read moreWednesday newspaper share tips: Wolseley, Circassia, Sage
28th Sep 2016 19:43
(ShareCast News) - Growth in the US market will continue to power Wolseley's performance, but with the benefit of the pound's fall on profits now behind it and faced with low demand from its UK and Nordic operations the shares look high enough at 14 times' earnings, The Times's Tempus said. In the f
Read moreFTSE 250 movers: Dead cat bounce in Circassia
21st Jun 2016 16:59
(ShareCast News) - High-tech components manufacturer Senior led the fallers on the mid-cap index after it issued a pre-close trading update on Tuesday, in which it reiterated that margins in the aerospace division will be lower in the first half of 2016. The FTSE 250 firm said activity in aerospace
Read moreLondon midday: Financials pace gains as Footsie keeps climbing
20th Jun 2016 12:29
(ShareCast News) - Stocks in London were continuing to move higher come midday on Monday, alongside the largest gain the pound in three months, with investors taking their cue from strong gains in Asia as Brexit polls showed the Remain campaign was in the lead. As of 12:03 BST, the FTSE 100 was 183.
Read moreLondon open: Stocks surge after latest poll results
20th Jun 2016 08:48
(ShareCast News) - Stocks in London surged at the start of trading, alongside the largest gain the pound in three months, with investors taking their cue from strong gains in Asia as Brexit polls showed the Remain campaign was in the lead. As of 08:43 BST the FTSE 100 was 145.82 points or 2.42% high
Read moreCircassia plummets after cat allergy drug fails placebo test
20th Jun 2016 07:23
(ShareCast News) - Shares in biopharmaceutical development company Circassia Pharmaceuticals plummeted on Monday morning, after it announced disappointing top-line results from its investigational cat allergy immunotherapy phase III study. At 0815 BST, shares in Circassia were down 55.86% at 119.3p.
Read moreCircassia to report Phase 3 trial results for cat allergy treatment in coming weeks
25th May 2016 17:26
(ShareCast News) - Circassia Pharmaceuticals kicked off phase-three trials for its grass allergy treatment, the second imunotherapy programme for which it was seeking regulatory approval, and said it was on-track to report the results of its phase-three clinical trials for its Cat allergy treatment
Read moreCircassia Pharmacuticals reports first revenue
11th Mar 2016 07:47
(ShareCast News) - Circassia Pharmaceuticals became a revenue-making business in 2015, and was making firm progress on a number of its products under development, it reported in its preliminary results on Friday. The FTSE 250 company published robust revenue growth through the calendar year through
Read more